{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-22-019486","form_type":"8-K","ticker":null,"cik":"0000008868","company_name":"AVON PRODUCTS INC","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.875670+00:00","generated_at":"2026-06-22T00:26:05.350280+00:00","sec_items":["2.05","2.06","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Avon Products approves closure of Suffern R&D facility, relocation to Brazil and Poland with $39M restructuring costs","bullets":["Board approved plan to close Suffern, NY R&D facility and relocate to Brazil and Poland by end of June 2024 fiscal quarter.","Expected non-recurring restructuring costs of approximately $39.0 million and capital expenditures of $10.0 million.","Potential impairment charge on fixed assets in the range of $35.0 million to $40.0 million.","Relocation aims to deliver Global Innovation Program and realize cost efficiencies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-22-019486","json":"https://secwatch.observer/filing/0000950103-22-019486.json","markdown":"https://secwatch.observer/filing/0000950103-22-019486.md","text":"https://secwatch.observer/filing/0000950103-22-019486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/8868/000095010322019486/0000950103-22-019486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/8868/000095010322019486/dp184155_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:26:05.350280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5615c6c0899f1849c5b15dffb71f772534301f9d","claim":"AVON PRODUCTS INC announced a impairment with charges of $35.0 million to $40.0 million affecting fixed assets related to Suffern facility closure.","evidence_excerpt":"Avon is also performing an impairment analysis over fixed assets and, as a result, expects to record a potential impairment charge in the range of $35.0 million to $40.0 million.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/8868/000095010322019486/0000950103-22-019486-index.htm","confidence":0.7,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"impairment"},{"label":"Charge","value":"$35.0 million to $40.0 million"},{"label":"Affected area","value":"fixed assets related to Suffern facility closure"}],"fact_type":"restructuring_charge"},{"claim_id":"8becb2a49ccca61a0347285f028256df58736c6d","claim":"AVON PRODUCTS INC announced a restructuring with charges of approximately $39.0 million affecting research and development facilities in Suffern, New York, relocated to Brazil and Poland.","evidence_excerpt":"development activities to Brazil and Poland. Avon expects to incur non-recurring restructuring costs in connection with the closure and relocation in the amount of approximately $39.0 million, to be incurred in the fiscal years ending December 31, 2022, 2023, 2024 and 2025 and capital expenditures relating to the infrastructure and facilities in Brazil and Poland","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/8868/000095010322019486/0000950103-22-019486-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $39.0 million"},{"label":"Affected area","value":"research and development facilities in Suffern, New York, relocated to Brazil and Poland"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}